NEW YORK (GenomeWeb) – Courtagen Life Sciences announced yesterday that it has signed an agreement to collaborate with Astellas Pharma for the early-stage development of therapeutics for mitochondrial disease.

Mitochondrial disease is a class of rare genetic disorders caused when cellular mitochondria do not properly produce energy. Its symptoms vary from patient to patient, but can include muscle weakness, neurological problems, developmental delays, and increased risk of infection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.